[Predictors for Presence of Residual Tumor in Follow-up Transurethral Resection of Bladder Tumors: Single Center Results]

Overview

Journal Urologe A

Specialty Urology

Date 2013 Jan 30

PMID 23358830

Citations 2

Authors

J Hartinger

R Haussermann

P Olbert

R Hofmann

A Hegele

Affiliations

Soon will be listed here.

Abstract

Background: European Association of Urology (EAU) guidelines recommend a follow-up transurethral resection of bladder tumors (reTUR-B) for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) 2-6 weeks after the initial resection. The purpose of this study was to find parameters which indicate the presence of residual tumor in reTUR-B and to evaluate the prognostic value.

Patients And Methods: The data from all patients treated with TUR-B between January 2005 and December 2008 were retrospectively evaluated. The residual tumor rate was correlated with age, sex, staging, grading, risk group, multifocality and surgeon's level of training.

Results: A total number of 555 TUR-B operations were carried out and 179 patients received reTUR-B according to the EAU guidelines. Age (p=0.8), sex (p=0.7), initial staging (p=0.2), initial grading (p=0.3) and surgeon's level of training (p=0.7) did not have an impact on the rate of residual tumor in reTUR-B. Tumors categorized as high risk according to the EAU risk score in initial TUR-B (p<0.01) and multifocality (p=0.01) were associated with significantly higher rates of residual tumor.

Conclusions: A reTUR-B is strongly indicated in high risk bladder tumors as well as multifocal tumors showing a significantly increased residual tumor rate. Other clinical parameters showed no prognostic value for the existence of residual tumor in reTUR-B.

Citing Articles

Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer.

Ferro M, Di Lorenzo G, Buonerba C, Lucarelli G, Russo G, Cantiello F J Cancer. 2018; 9(22):4250-4254.

PMID: 30519326 PMC: 6277616. DOI: 10.7150/jca.26129.

[T1 bladder cancer: role of documentation for bladder tumor findings and targeted second resection].

Lazica D, Bottcher S, Degener S, von Rundstedt F, Brandt A, Storkel S Urologe A. 2013; 52(8):1110-7.

PMID: 23754611 DOI: 10.1007/s00120-013-3206-5.

References

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6):997-1008. DOI: 10.1016/j.eururo.2011.03.017. View

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M . A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011; 186(6):2158-67. DOI: 10.1016/j.juro.2011.07.076. View

Herr H . The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162(1):74-6. DOI: 10.1097/00005392-199907000-00018. View

Brausi M, Collette L, Kurth K, van der Meijden A, Oosterlinck W, Witjes J . Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41(5):523-31. DOI: 10.1016/s0302-2838(02)00068-4. View

Vogeli T, Grimm M, Simon X, Ackermann R . [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma]. Urologe A. 2002; 41(5):470-4. DOI: 10.1007/s00120-001-0158-y. View

Schips L, Augustin H, Zigeuner R, Galle G, Habermann H, Trummer H . Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?. Urology. 2002; 59(2):220-3. DOI: 10.1016/s0090-4295(01)01522-9. View

Divrik T, Yildirim U, Eroglu A, Zorlu F, Ozen H . Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?. J Urol. 2006; 175(4):1258-61. DOI: 10.1016/S0022-5347(05)00689-0. View

10.

Brauers A, Buettner R, Jakse G . Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol. 2001; 165(3):808-10. View

11.

Zurkirchen M, Sulser T, Gaspert A, Hauri D . Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int. 2004; 72(2):99-102. DOI: 10.1159/000075961. View

12.

Schwaibold H, Sivalingam S, May F, Hartung R . The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006; 97(6):1199-201. DOI: 10.1111/j.1464-410X.2006.06144.x. View

13.

Grimm M, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli T . Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003; 170(2 Pt 1):433-7. DOI: 10.1097/01.ju.0000070437.14275.e0. View